Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8045963 | 0.89 | MAPK14 (0.58) | MAPK14PTPN1SMN1; SMN2TP53NR3C1 | |
| SCHEMBL3373304 | 0.89 | PTPN1 (0.55) | MAPK14PTPN1KEAP1SCN9ARIPK2 | |
| SCHEMBL25344549 | 0.87 | MAPK14 (0.57) | MAPK14SMN1; SMN2TP53NR3C1GPR35 | |
| SCHEMBL20162796 | 0.84 | MAPK14 (0.54) | MAPK14PTPN1SMN1; SMN2TP53NR3C1 | |
| SCHEMBL30038196 | 0.84 | MAPK14 (0.54) | MAPK14PTPN1SMN1; SMN2TP53NR3C1 | |
| SCHEMBL6052137 | 0.83 | SMN1; SMN2 (0.52) | MAPK14SMN1; SMN2TP53GPR35 | |
| SCHEMBL3376470 | 0.82 | MAPK14 (0.77) | MAPK14PTPN1SMN1; SMN2SCN9ARIPK2 | |
| SCHEMBL27718175 | 0.82 | MAPK14 (0.48) | MAPK14PTPN1SCN9A | |
| SCHEMBL31117130 | 0.81 | RAB9A (0.59) | MAPK14SMN1; SMN2TP53 | |
| SCHEMBL4872984 | 0.81 | RAB9A (0.59) | MAPK14SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | GLAXO GROUP LIMITED | 2012-11-01 | — | — | US | disclosed |
| US-8247377-B2 | Non-steroidal glucocorticoid inhibitors and their use in treating inflammation, allergy and auto-immune conditions | GLAXO GROUP LIMITED (GB) | 2012-08-21 | — | — | US | disclosed |
| EP-2029549-B1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORICOID RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2010-11-10 | — | — | EP | disclosed |
| US-20100234441-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-09-16 | — | — | US | disclosed |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2010-02-11 | — | — | US | disclosed |
| EP-2099766-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | Glaxo Group Limited (GB) | 2009-09-16 | — | — | EP | disclosed |
| US-20080207725-A1 | Phenyl-Pyrazole Derivatives as Non-Steroidal Glucocorticoid Receptor Ligands | GLAXO GROUP LIMITED, A CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207725-A1 | Phenyl-Pyrazole Derivatives as Non-Steroidal Glucocorticoid Receptor Ligands | GLAXO GROUP LIMITED, A CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2008074814-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
| EP-1896438-A1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2008-03-12 | — | — | EP | disclosed |
| WO-2007000334-A1 | PHENYL-PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234441-A1 | NOVEL COMPOUNDS | LTB4R2, TSLP, LTB4R | MAPK14 1393/4885PTPN1 3482/4885SMN1; SMN2 4171/4885 |
| US-20080207725-A1 | Phenyl-Pyrazole Derivatives as Non-Steroidal Glucocorticoid Receptor Ligands | NR3C1, NR3C2, NR5A1 | MAPK14 819/4885PTPN1 430/4885SMN1; SMN2 4856/4885 |
| US-20100035926-A1 | PYRAZOLE DERIVATIVES AS NON-STEROIDAL GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, CYP11B2 | MAPK14 602/4885PTPN1 593/4885SMN1; SMN2 4873/4885 |
| US-20120277279-A1 | Non-Steroidal Glucocorticoid Inhibitors and Their Use in Treating Inflammation, Allergy and Auto-Immune Conditions | NR3C1, SERPINA6, PTGS1 | MAPK14 530/4885PTPN1 331/4885SMN1; SMN2 4794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.